Looking for stocks you don't have to babysit? Consider these three stocks.
The company reported fourth-quarter and full-year 2018 earnings and guidance for 2019.
The pharmaceutical company may have proved Wall Street wrong, but it has a long way to go to reach its full potential -- and that's a good thing for investors.
The gene therapy company saw another peer get gobbled up in an acquisition.
The wait is over for patient shareholders: This solar power system component business is finally profitable.
A fast-growing pharma and a leader in solar-power hardware have soared in 2019, but they're still buys for investors with a long-term mind-set.
The refining king has been the worst-performing supermajor in the last three years. Can it ride the Permian Basin to a turnaround?
Colorado is taking steps to reduce its citizens' exposure to the financial risks posed by aging coal-fired power plants. Other states should take note.
These two companies saw their shares double in 2018. They're still buys for long-term investors.
Two down-on-their-luck growth stocks are worth a closer look after a poor start to 2019.
Each company promises to bring a massive LNG export terminal online by 2023. Which is worth your patience?
These fast-growing businesses are on the cusp of greatness, even if they're not on your radar.
Plants aren't always the perfect medium for producing high-value compounds. Turns out, cannabinoids can be brewed with microbes instead.
European experts don't have the same concerns over the company's lead drug as their American peers, recommending it for patients with type 1 diabetes.
The company announced fourth-quarter and full-year 2018 earnings.
The oil and gas leader has been the best performer among supermajors in the last three years. Does this oil stock still have room to run?
The medical technology company issued fourth-quarter and full-year 2018 earnings.
A new player has emerged in a bid to acquire the materials manufacturer.
The small biotech met 2018 guidance and expects another year of growth, but one segment's growth disappoints.
The pharma company announced fourth-quarter and full-year 2018 operating results.